78 related articles for article (PubMed ID: 27405253)
21. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
[TBL] [Abstract][Full Text] [Related]
22. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking.
Blaising J; Lévy PL; Gondeau C; Phelip C; Varbanov M; Teissier E; Ruggiero F; Polyak SJ; Oberlies NH; Ivanovic T; Boulant S; Pécheur EI
Cell Microbiol; 2013 Nov; 15(11):1866-82. PubMed ID: 23701235
[TBL] [Abstract][Full Text] [Related]
23. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
Fukasawa M
Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
[TBL] [Abstract][Full Text] [Related]
24. Mouse monoclonal antibody towards e1 specific epitope blocks viral entry and intracellular viral replication in vitro.
Tabll AA; Moustafa RI; El Abd YS; Bader El Din NG; El-Shenawy R; Yousef H; Hussein M; Dawood RM; Omran MH; El-Awady MK
J Immunoassay Immunochem; 2014; 35(1):60-73. PubMed ID: 24063617
[TBL] [Abstract][Full Text] [Related]
25. Glucocorticosteroids increase cell entry by hepatitis C virus.
Ciesek S; Steinmann E; Iken M; Ott M; Helfritz FA; Wappler I; Manns MP; Wedemeyer H; Pietschmann T
Gastroenterology; 2010 May; 138(5):1875-84. PubMed ID: 20152835
[TBL] [Abstract][Full Text] [Related]
26. Entry of pseudotyped hepatitis C virus into primary human hepatocytes depends on the scavenger class B type I receptor.
Régeard M; Trotard M; Lepère C; Gripon P; Le Seyec J
J Viral Hepat; 2008 Dec; 15(12):865-70. PubMed ID: 19087225
[TBL] [Abstract][Full Text] [Related]
27. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain.
Chi X; Niu Y; Cheng M; Liu X; Feng Y; Zheng F; Fan J; Li X; Jin Q; Zhong J; Li YP; Yang W
Sci Rep; 2016 Apr; 6():25224. PubMed ID: 27121372
[TBL] [Abstract][Full Text] [Related]
28. New cell culture models of hepatitis C virus entry, replication, and virus production.
Lindenbach BD
Gastroenterology; 2010 Oct; 139(4):1090-3. PubMed ID: 20797436
[No Abstract] [Full Text] [Related]
29. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
30. Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection.
Yoshida T; Takayama K; Kondoh M; Sakurai F; Tani H; Sakamoto N; Matsuura Y; Mizuguchi H; Yagi K
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):119-24. PubMed ID: 22093821
[TBL] [Abstract][Full Text] [Related]
31. Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro.
Xia Y; Cheng X; Blossey CK; Wisskirchen K; Esser K; Protzer U
J Immunol Res; 2017; 2017():4828936. PubMed ID: 28367455
[TBL] [Abstract][Full Text] [Related]
32. [Novel strategies for preventing viral hepatitis C recurrence after liver transplantation].
Stoll-Keller F; Fafi-Kremer S; Wolf P; Doffoël M; Baumert T
Bull Acad Natl Med; 2008 Nov; 192(8):1657-67; discussion 1667-8. PubMed ID: 19445379
[TBL] [Abstract][Full Text] [Related]
33. Virology: Final entry key for hepatitis C.
Pietschmann T
Nature; 2009 Feb; 457(7231):797-8. PubMed ID: 19212389
[No Abstract] [Full Text] [Related]
34. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C virus is restricted at both entry and replication in mouse hepatocytes.
Park IW; Ndjomou J; Fan Y; Henao-Mejia J; He JJ
Biochem Biophys Res Commun; 2009 Sep; 387(3):489-93. PubMed ID: 19619513
[TBL] [Abstract][Full Text] [Related]
36. The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.
Perrault M; Pécheur EI
Biochem J; 2009 Oct; 423(3):303-14. PubMed ID: 19807698
[TBL] [Abstract][Full Text] [Related]
37. Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro.
Sandmann L; Wilson M; Back D; Wedemeyer H; Manns MP; Steinmann E; Pietschmann T; von Hahn T; Ciesek S
Antiviral Res; 2012 Oct; 96(1):51-8. PubMed ID: 22842003
[TBL] [Abstract][Full Text] [Related]
38. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro.
Hang X; Peng H; Song H; Qi Z; Miao X; Xu W
J Virol Methods; 2015 Sep; 222():150-7. PubMed ID: 26116793
[TBL] [Abstract][Full Text] [Related]
39. CD36 is a co-receptor for hepatitis C virus E1 protein attachment.
Cheng JJ; Li JR; Huang MH; Ma LL; Wu ZY; Jiang CC; Li WJ; Li YH; Han YX; Li H; Chen JH; Wang YX; Song DQ; Peng ZG; Jiang JD
Sci Rep; 2016 Feb; 6():21808. PubMed ID: 26898231
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus entry.
Zeisel MB; Felmlee DJ; Baumert TF
Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
